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Objectives: The aim of this study is to provide an overview of the quality of health 
economic evaluations (HEEs) of prediction models, the evidence used, and the chal-
lenges. MethOds: The databases Medline, Embase, Econlit, and the NHS Economic 
Evaluations Database were systematically searched for HEEs of diagnostic and prog-
nostic risk prediction models. The included HEEs were evaluated on their meth-
odological quality using the Drummond checklist. Furthermore, an item list was 
developed incorporating descriptive items on the HEE, specific items on the HEE of 
prediction models, and statistical characteristics of the prediction model that could 
be incorporated into the evaluation. Results: The database search resulted in 791 
unique papers, from which 653 were excluded based on abstract. After assessing 
full texts, 17 HEEs (all cost-utility studies) were included. A prediction model was 
compared to current practice in 11 HEEs and to an extended prediction model in 6 
HEEs. On a 35-point scale the quality score ranged from 17 to 32 (median 25). In 7 
papers there was no overlap between authors of the initial prediction model paper 
and those of the corresponding HEE. In 5 papers individuals were classified based 
on a single (set of) threshold(s); based on guidelines in 4 papers and once on expert 
opinion. In 8 papers the classification threshold was optimized in the CEA itself. 
A probabilistic sensitivity analysis was not included in 7 papers and uncertainty 
around predicted risks was only taken into account once. cOnclusiOns: In most 
papers limited (prediction model) details were available. Potentially due to this lack 
of evidence and a lack of specific guidelines on HEE of prediction models, a large 
variety in the quality and methodology was observed. This variation may complicate 
the validation and interpretation of HEE results and thereby the decision making 
on implementation of prediction models in practice.
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Objectives: To understand the key functional differences between conventional 
cost-effectiveness Excel and web based model types. MethOds: An online survey 
consisting 18 end users and 5 model owners (n= 23) was conducted. Respondents 
were asked to rate key criteria of both model types on a scale from 0 to 10. Model 
types were compared with the following 13 criterias: model execution speed and 
size, general functionality support, accessibility, usability, model management and 
versioning, ease of localization, ease of model core modification, sharing, review 
process, usage analytics, integration with other content. No weighting to the scor-
ing across criteria was applied. Results: Results of the survey indicate that web 
based models outperform standalone models in 10 of the 13 criteria assessed. Model 
review process, ease of model core modification and execution speed was rated 
higher for conventional standalone Excel models. 80% of model owners and 78% of 
model users assigned higher overall score for web based models compared to Excel 
models. cOnclusiOns: Web based models offer advantages primarily related to 
model usage and lifecycle management. These models can be viewed on any hard-
ware device or browser, thus overcoming the limitations of Excel models. The use of 
latest web technologies such as JavaScript, HTML5 and CSS3 improve user experi-
ence in model adaptation and presentation to end audience. Usage analytics, smart 
versioning, web sharing and automatic updates are the functional advantages that 
can not be achieved with conventional Excel models due to technical limitations.
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Objectives: To validate a model for quantifying the COPD disease progression 
against both the data used to generate the model (internal validation) and clinical 
trial data not used in the model’s development (external validation). MethOds: 
A model representing causal relationships between central disease attributes 
(lung function, exacerbations, symptoms and exercise capacity) and final out-
comes (survival, quality of life, cost) was developed based on the Evaluation of 
COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study 
dataset. Model predicted annual outcomes were compared to the corresponding 
annual observed data from ECLIPSE (n= 2,164) and TOwards a Revolution in COPD 
Health (TORCH) (n= 6,108) trials based on fitting the model baseline parameters to 
reflect each specific study population. Results: The model accurately predicted 
the ECLIPSE outcomes in at least two of the three annual time points within the 
95% confidence interval (CI) of the observed data for survival, FEV1% predicted, 
and annual exacerbations (per patient per year [PPPY]. The model predicted 9.0 
metres annual decline in Six Minute Walk Distance compared to ECLIPSE observed 
data of 5.7 metres decline. The model accurately predicted the TORCH placebo 
outcomes in at least two of the three annual time points within the 95%CI of the 
observed data for FEV decline and annual exacerbations PPPY. The model over 
predicted survival by 8% (absolute) compared to TORCH observed data at year 
3. cOnclusiOns: As expected, the model more accurately predicted the ECLIPSE 
observed outcomes in the internal validation exercise, than TORCH outcomes in 
the external validation.
years (QALYs). Thus, considerations on QoL outcomes in the clinical trial design 
phase may lead to better optimized reimbursement submissions. The objective 
of this study was to develop a trial simulation model that is capable of addressing 
complex research questions, provides flexibility to test various assumptions, and 
predicts expected QALY outcomes. MethOds: A patient-level simulation model 
was developed using hypothetical data in oncology. The model considered two treat-
ments reflecting the common design of a pivotal trial. Individual survival times 
and time to progression data were simulated. Hazard ratios were used to include 
treatment effects. Using the simulated individual level data, a multistate life table 
model was constructed with three health states: pre-progression (with and without 
adverse events), post-progression, and dead. Utility and disutility values derived 
from literature were attached to the number of patients in each health state at a 
given point in time. Differences between the treatment arms were derived in terms 
of survival, QALYs, and the uncertainty around those (e.g. probability distribution, 
P-value). Results: The trial simulation model assessed various patient number 
scenarios to obtain the smallest sample size that provided a statistically signifi-
cant minimum clinically meaningful QALY difference between the treatments. 
Simulations were performed (e.g. testing the effect of different survival profile sce-
narios, utility values) to assess the robustness of the results. cOnclusiOns: The 
presented trial simulation model provided a flexible tool to inform clinical trial 
design considering QoL outcomes. The model can be also useful for manufacturers 
for pricing or investment decisions.
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Objectives: To identify and assess mathematical models predicting the relative 
effectiveness of drug treatments in “real world” populations, based on data from 
randomized control trials and other sources of evidence. MethOds: Systematic 
review of mathematical modelling studies addressing the step from relative effi-
cacy to relative effectiveness. We identified eligible studies through electronic and 
manual searches of MEDLINE and EMBASE databases, selected websites and refer-
ence lists of relevant papers. Two reviewers screened the articles independently 
and extracted study characteristics such as model type, disease area, validation 
and software used via an extraction form. Results: Eight papers met the inclusion 
criteria covering four broad modelling approaches: multi-state models, simulation-
based approaches, mechanistic models, and classical regression based models. The 
multi-state models were the predominant class of models. These models are defined 
as time-dependent stochastic processes with discrete event space. Most examples 
belonged to the special case of Markov multi-state models. Multi-state models 
were applied at the level of population groups or at the individual patient level. 
The other approaches we identified were less frequent. Discrete event simulation 
was used in one paper. This approach is entirely based on simulations. One article 
described a mechanistic model based on ordinary differential equations, which 
are typically derived from biological knowledge and first principles. Finally, more 
classical regression techniques from survival analysis were used in two papers. Six 
articles included models built for cardiovascular indications, the remaining ones 
covered oncology and neurosciences. Internal or external model validation was 
presented in six papers, while two papers considered only sensitivity analysis to 
evaluate the model performance. cOnclusiOns: This review shows the range of 
models currently used for predicting the relative effectiveness of drug interventions 
in real world patient populations. They complement the available tools for evidence 
synthesis in comparative effectiveness research.
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Objectives: To perform cost-effectiveness analysis (CEA) for routine use of a trans-
parent dressing integrating a chlorhexidine gluconate (CHG) -containing gel pad 
versus standard transparent dressings, with a classical decision tree model and 
a Non-Homogeneous Markov Model (NHMM) previously developed. MethOds: 
Clinical efficacy data was extracted from a multicentre randomized controlled trial 
(RCT) with 1,879 patients and economical data obtained from micro and macro-
costing published studies. The baseline method is a NHMM previously developed in 
Microsoft Excel® with VBA using the same data sources. The decision tree was built 
with the TreeAge Pro® software 2013. One-way deterministic (DSA) and probabilistic 
sensitivity (PSA) analyses were conducted on key clinical and economic param-
eters. Results: Based on the decision-tree model, the CHG-dressing is a dominant 
strategy compared to standard dressings. The intervention prevents 13.5 infections 
per 1,000 patients and saves € 157 per patient. These results are robust across a 
range of values for several parameters in DSA. The PSA with the NHMM resulted in 
11.8 infections avoided per 1,000 patients (95%CI: [3.85; 19.64)]) and a mean extra 
cost of € 141 per patient (95%CI: [€ -975; € 1,258]) when using antimicrobial dress-
ing. Effectiveness as calculated by both models is similar while cost estimations 
diverge. cOnclusiOns: Decision-tree and the NHMM are structurally different and 
even though their outcomes cannot be directly compared, they were coherent. The 
decision-tree model indicates that CHG-dressings are cost-saving and a dominant 
preventative strategy for CRBSIs. The Markov model supports cost-effectiveness 
compared to standard dressing. The main disadvantages of the decision-tree are the 
inability to integrate changes among health states during the ICU stay and to simu-
late possible observable trajectories in the patient history. The structure of the non-
homogeneous Markov model does not allow DSA for the incidence of the disease.
